BC Week In Review | Feb 22, 2016
Clinical News

Toctino alitretinoin: Development discontinued

GSK discontinued its Toctino U.S. program. Basilea, which granted GSK exclusive, worldwide rights to alitretinoin in 2012, has the option to reacquire U.S. rights. In 2015, Almirall S.A. (Madrid:ALM, Barcelona, Spain) granted GSK distribution rights...
BC Week In Review | Dec 21, 2015
Company News

GlaxoSmithKline, Almirall deal

GlaxoSmithKline granted Almirall rights to develop and commercialize Veltin Gel clindamycin/tretinoin worldwide and Altabax retapamulin in the U.S. in exchange for distribution rights to Toctino alitretinoin in Austria, the Czech Republic, Italy, the Netherlands, Poland,...
BC Week In Review | Jun 18, 2012
Company News

Basilea, GlaxoSmithKline sales and marketing update

Basilea granted GlaxoSmithKline's Stiefel Laboratories Inc. subsidiary exclusive, worldwide rights to the Swiss company's only marketed drug, eczema therapy Toctino alitretinoin. Basilea will receive L146 million ($226.3 million) up front and is eligible for L30-L50...
BioCentury | Jun 18, 2012
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 6/15 cls Basilea Pharmaceutica AG (SIX:BSLN) Jefferies Philippa Gardner Price target Hold 3% CHF44.05 Gardner raised her target to CHF51 from CHF45 after Basilea...
BioCentury | Jun 18, 2012
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Arena Pharmaceuticals Inc. (NASDAQ:ARNA) gained $1.78 (27%) to $8.40 last week ahead of a June 27 PDUFA date for an NDA for lorcaserin to treat obesity. BTG plc (LSE:BTG) was off 1.80p to...
BC Extra | Jun 12, 2012
Top Story

Basilea out-licenses Toctino to Stiefel

Basilea Pharmaceutica AG (SIX:BSLN) granted Stiefel Laboratories Inc. exclusive, worldwide rights to the Swiss company's only marketed drug, eczema therapy Toctino alitretinoin. Basilea will receive L146 million ($226.3 million) up front and is eligible for...
BioCentury | Apr 2, 2012
Finance

Doubling down

Biotech investors lifted valuations across the board last quarter and made a handful of big bets that were driven by potential acquisitions, lawsuit settlements, strong earnings and positive clinical and regulatory news. At least one...
BioCentury | Apr 2, 2012
Finance

Thinking small again

Buysiders shied away from small and micro-cap stocks over the last few years as poor performance and inadequate financing plagued these groups. But many investors now see them as undervalued. These include winners from last...
BC Week In Review | Mar 19, 2012
Clinical News

Toctino alitretinoin: Phase III data

Top-line data from the double-blind, U.S. Phase III HANDEL trial in 596 patients with severe chronic hand eczema unresponsive to topical corticosteroids showed that once-daily 30 mg oral Toctino for up to 6 months met...
BioCentury | Mar 19, 2012
Finance

Highlights of weekly biotech stock moves

Active Biotech AB (SSE:ACTI) gained SEK9.70 (24%) to SEK49.40 on Thursday after partner Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) said it plans to submit an MAA to EMA in 2H12 for laquinimod in multiple sclerosis (MS)....
Items per page:
1 - 10 of 137